{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+Lupus+Nephritis",
    "query": {
      "condition": "Refractory Lupus Nephritis"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 18,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+Lupus+Nephritis&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-26T06:21:58.729Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06708845",
      "title": "US Zamto-cel Autoimmune Diseases",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lupus Nephritis",
        "Systemic Lupus Erythematosus",
        "Systemic Sclerosis (SSc)",
        "Diffuse Cutaneous Systemic Sclerosis"
      ],
      "interventions": [
        {
          "name": "zamtocabtagene autoleucel",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Miltenyi Biomedicine GmbH",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2026-07",
      "completion_date": "2028-07",
      "has_results": false,
      "last_update_posted_date": "2026-06-11",
      "last_synced_at": "2026-06-26T06:21:58.729Z",
      "location_count": 1,
      "location_summary": "Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06708845"
    },
    {
      "nct_id": "NCT05938725",
      "title": "KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Lupus Nephritis",
        "Lupus Nephritis - World Health Organization (WHO) Class III",
        "Lupus Nephritis - WHO Class IV"
      ],
      "interventions": [
        {
          "name": "KYV-101 anti-CD19 CAR-T cell therapy",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Standard lymphodepletion regimen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Kyverna Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2023-04-28",
      "completion_date": "2027-08",
      "has_results": false,
      "last_update_posted_date": "2025-10-29",
      "last_synced_at": "2026-06-26T06:21:58.729Z",
      "location_count": 6,
      "location_summary": "Palo Alto, California • Denver, Colorado • Worcester, Massachusetts + 3 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Worcester",
          "state": "Massachusetts"
        },
        {
          "city": "Great Neck",
          "state": "New York"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05938725"
    },
    {
      "nct_id": "NCT06377228",
      "title": "A Study of TAK-007 in Adults With Refractory Lupus Nephritis (LN) or Refractory Systemic Sclerosis (SSc)",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Refractory Lupus Nephritis",
        "Refractory Systemic Sclerosis"
      ],
      "interventions": [
        {
          "name": "TAK-007",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Chemotherapy Agents",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 0,
      "start_date": "2025-06-13",
      "completion_date": "2030-09-02",
      "has_results": false,
      "last_update_posted_date": "2025-04-06",
      "last_synced_at": "2026-06-26T06:21:58.729Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06377228"
    },
    {
      "nct_id": "NCT06935474",
      "title": "C-CAR168 CAR T Cell Therapy for Refractory Autoimmune Disease",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Lupus Nephritis (LN)"
      ],
      "interventions": [
        {
          "name": "C-CAR168",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "AbelZeta Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 24,
      "start_date": "2026-07",
      "completion_date": "2030-06",
      "has_results": false,
      "last_update_posted_date": "2026-02-03",
      "last_synced_at": "2026-06-26T06:21:58.729Z",
      "location_count": 1,
      "location_summary": "Rockville, Maryland",
      "locations": [
        {
          "city": "Rockville",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06935474"
    },
    {
      "nct_id": "NCT06544330",
      "title": "A Phase 1 Study of SYNCAR-001 + STK-009 Without Conditioning Chemotherapy (Lymphodepletion) in Subjects With Severe, Refractory Systemic Autoimmune Rheumatic Disease",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Systemic Lupus Erythematosus",
        "Lupus Nephritis",
        "Systemic Sclerosis"
      ],
      "interventions": [
        {
          "name": "SYNCAR-001",
          "type": "DRUG"
        },
        {
          "name": "STK-009",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Synthekine",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2025-04-29",
      "completion_date": "2041-04",
      "has_results": false,
      "last_update_posted_date": "2025-11-04",
      "last_synced_at": "2026-06-26T06:21:58.729Z",
      "location_count": 5,
      "location_summary": "Scottsdale, Arizona • Hackensack, New Jersey • Manhasset, New York + 2 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "Manhasset",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06544330"
    },
    {
      "nct_id": "NCT07038447",
      "title": "A Study of KITE-363 in Participants With Refractory Autoimmune Diseases",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Systemic Lupus Erythematosus",
        "Lupus Nephritis",
        "Systemic Sclerosis",
        "Idiopathic Inflammatory Myopathy"
      ],
      "interventions": [
        {
          "name": "KITE-363",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Kite, A Gilead Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 52,
      "start_date": "2025-07-02",
      "completion_date": "2029-07",
      "has_results": false,
      "last_update_posted_date": "2026-06-16",
      "last_synced_at": "2026-06-26T06:21:58.729Z",
      "location_count": 4,
      "location_summary": "Duarte, California • Stanford, California • Tampa, Florida + 1 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07038447"
    },
    {
      "nct_id": "NCT06064929",
      "title": "A Study to Learn More About the Safety and Effects of Felzartamab in Adults With Lupus Nephritis Aged 18 to 75 Years Old",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lupus Nephritis"
      ],
      "interventions": [
        {
          "name": "Felzartamab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "HI-Bio, A Biogen Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 14,
      "start_date": "2023-11-01",
      "completion_date": "2026-06-30",
      "has_results": false,
      "last_update_posted_date": "2025-12-31",
      "last_synced_at": "2026-06-26T06:21:58.729Z",
      "location_count": 14,
      "location_summary": "La Jolla, California • San Francisco, California • Stanford, California + 9 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Columbus",
          "state": "Georgia"
        },
        {
          "city": "Lawrenceville",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06064929"
    },
    {
      "nct_id": "NCT07115745",
      "title": "A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Refractory Autoimmune Diseases"
      ],
      "interventions": [
        {
          "name": "BMS-986515",
          "type": "GENETIC"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Tocilizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "DRUG"
      ],
      "sponsor": "Juno Therapeutics, Inc., a Bristol-Myers Squibb Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 125,
      "start_date": "2025-09-04",
      "completion_date": "2030-08-16",
      "has_results": false,
      "last_update_posted_date": "2026-05-27",
      "last_synced_at": "2026-06-26T06:21:58.729Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • Durham, North Carolina",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07115745"
    },
    {
      "nct_id": "NCT06294236",
      "title": "Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lupus Erythematosus",
        "Systemic Lupus Erythematosus",
        "SLE (Systemic Lupus)",
        "Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis",
        "Granulomatous Polyangiitis",
        "Microscopic Polyangiitis"
      ],
      "interventions": [
        {
          "name": "SC291",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sana Biotechnology",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 7,
      "start_date": "2024-04-29",
      "completion_date": "2028-03",
      "has_results": false,
      "last_update_posted_date": "2025-11-25",
      "last_synced_at": "2026-06-26T06:21:58.729Z",
      "location_count": 5,
      "location_summary": "Aurora, Colorado • Atlanta, Georgia • Baltimore, Maryland + 2 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06294236"
    },
    {
      "nct_id": "NCT07053800",
      "title": "Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lupus Nephritis"
      ],
      "interventions": [
        {
          "name": "Obecabtagene autoleucel",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Autolus Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "12 Years to 65 Years"
      },
      "enrollment_count": 35,
      "start_date": "2026-01-16",
      "completion_date": "2029-10",
      "has_results": false,
      "last_update_posted_date": "2026-06-23",
      "last_synced_at": "2026-06-26T06:21:58.729Z",
      "location_count": 2,
      "location_summary": "Syracuse, New York • San Antonio, Texas",
      "locations": [
        {
          "city": "Syracuse",
          "state": "New York"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07053800"
    }
  ]
}